Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:BEAT

HeartBeam Q3 2026 Earnings Date & Estimates

HeartBeam logo
$0.43 +0.04 (+9.82%)
Closing price 04:00 PM Eastern
Extended Trading
$0.42 -0.01 (-2.20%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HeartBeam is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from HeartBeam in Q3 2026

HeartBeam is expected to post earnings of -$0.09 per share on revenue of $0.08 million. In the same quarter a year earlier HeartBeam reported -$0.15 per share. HeartBeam last reported on August 13, 2026, posting -$0.10 per share and missing the -$0.0860 consensus estimate. HeartBeam has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.09
Expected Revenue
$0.08 million
Prior-Year EPS
-$0.15

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.10 (Missed by -$0.0140)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

HeartBeam Q3 2026 Earnings FAQ

HeartBeam (NASDAQ:BEAT) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

HeartBeam's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect HeartBeam to post earnings of -$0.09 per share for Q3 2026.

The consensus revenue estimate for HeartBeam is $0.08 million for Q3 2026.

HeartBeam Earnings Headlines

HeartBeam Joins Philips-Led EXIT-CVD Consortium For Cardiovascular Research In Europe; Stock Up
October 15 at 5:36 PM  |  rttnews.comhttps://www.rttnews.com/3699440/heartbeam-joins-philips-led-exit-cvd-consortium-for-cardiovascular-research-in-europe-stock-up.aspx
HeartBeam (NASDAQ:BEAT) Upgraded at Wall Street Zen
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104257
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
October 15 at 1:00 AM  |  Profits Run (Ad)
Penny Stocks To Watch Now - October 5th
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31094397
Heartbeam Inc. (BEAT)
October 6, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/insider-trading/company/heartbeam+inc/1779372/news/
HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System
October 5, 2026  |  benzinga.comhttps://www.benzinga.com/news/fda/26/10/62172027/heartbeam-secures-fda-designation-for-at-home-heart-attack-detection-system?utm_source=snapi
See More HeartBeam Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HeartBeam? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartBeam and other key companies, straight to your email.

About HeartBeam

HeartBeam (NASDAQ:BEAT) is a medical technology company developing portable cardiac-monitoring solutions designed to help detect and evaluate heart conditions outside traditional clinical settings. Its technology is intended to provide patients and healthcare professionals with more comprehensive electrocardiogram (ECG) information than conventional single-lead wearable devices.

The company’s primary product is the HeartBeam AIMIGo system, a compact, cable-free device that records a three-dimensional, vector-based ECG. Used with a mobile application, the system is designed to capture cardiac data when symptoms occur and share the resulting information with healthcare providers for review. HeartBeam’s platform is focused particularly on the remote assessment of possible cardiac events, including symptoms that may be associated with heart attacks.

HeartBeam’s technology is being developed for use in the United States and other healthcare markets where remote cardiac monitoring and digital health services are expanding. The company is headquartered in Santa Clara, California, and has focused its business on developing and commercializing its proprietary ECG platform rather than operating as a diversified medical-device manufacturer.

View HeartBeam Profile
Earnings Tools